EHVVF - EHAVE, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.0020
+0.0003 (+17.65%)
As of 02:18PM EDT. Market open.
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close0.0017
Open0.0023
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0020 - 0.0023
52 Week Range0.0015 - 0.0096
Volume18,727
Avg. Volume279,992
Market Cap756,364
Beta (5Y Monthly)2.27
PE Ratio (TTM)N/A
EPS (TTM)-0.0400
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for EHVVF

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • GlobeNewswire

    Ehave Provides Progress Update on its HPPD Study with University of Melbourne

    Potential of monetizing HPPD research by identifying biomarkers to identify individuals who have a higher risk of developing HPPD if they take psychedelicsMIAMI, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Ehave, Inc. (OTC Pink: EHVVF) (the "Company"), a Healthcare Analytics provider with interests in the psychedelic and mental health sectors, is pleased to announce it has completed the first phase of its series of studies with the University of Melbourne to determine the cause and possible cure for hallu

  • GlobeNewswire

    FDA Grants Ehave Consent to Proceed With Its Clinical Study on Intravenous Ketamine Infusion for Major Depressive Disorder

    Ehave study "An open label study of electrographic responses pre, during and post, a low dose, weekly intravenous ketamine infusion for 4 weeks, in a study population with major depression disorder" approved by FDAMIAMI, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Ehave, Inc., (OTC Pink: EHVVF) (the “Company”), a Healthcare Analytics provider with interests in the psychedelic and mental health sectors, announced today that it received confirmation from the U.S. Food and Drug Administration ("FDA") that it

  • GlobeNewswire

    Ehave Shareholder from CEO Ben Kaplan and Corporate Update

    MIAMI, Dec. 07, 2022 (GLOBE NEWSWIRE) -- Ehave, Inc., (OTC Pink: EHVVF) (the “Company”), a Healthcare Analytics provider with interests in the psychedelic and mental health sectors, today issued a letter to shareholders from its Chief Executive Officer, Ben Kaplan. Dear Fellow Shareholders As 2022 draws to a close, many of us will reflect on a year that saw global economic activity experiencing a broad-based and sharper-than-expected slowdown, increased inflation higher than we have seen in seve